Zhejiang Xianju Pharmaceutical Co.,Ltd.

SZSE:002332 Rapporto sulle azioni

Cap. di mercato: CN¥12.0b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Zhejiang Xianju PharmaceuticalLtd Crescita futura

Future criteri di controllo 3/6

Zhejiang Xianju PharmaceuticalLtd is forecast to grow earnings and revenue by 20% and 14.7% per annum respectively. EPS is expected to grow by 19.9% per annum. Return on equity is forecast to be 12.3% in 3 years.

Informazioni chiave

20.0%

Tasso di crescita degli utili

19.9%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili18.8%
Tasso di crescita dei ricavi14.7%
Rendimento futuro del capitale proprio12.3%
Copertura analitica

Good

Ultimo aggiornamento01 Aug 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Will Pay A Dividend Of CN¥0.30

Jun 02
Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Will Pay A Dividend Of CN¥0.30

Estimating The Fair Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

Apr 15
Estimating The Fair Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

There Is A Reason Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Price Is Undemanding

Mar 05
There Is A Reason Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Price Is Undemanding

Previsioni di crescita degli utili e dei ricavi

SZSE:002332 - Stime future degli analisti e dati finanziari passati (CNY Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20266,3001,007N/A1,0196
12/31/20255,444829N/A9286
12/31/20244,711679N/A7396
3/31/20244,204581385635N/A
12/31/20234,123563361595N/A
9/30/20234,164692493732N/A
3/31/20234,288755414673N/A
1/1/20234,380749327609N/A
9/30/20224,493689239535N/A
6/30/20224,442676277552N/A
3/31/20224,405636318599N/A
1/1/20224,357619409658N/A
9/30/20214,402605667807N/A
6/30/20214,391573644779N/A
3/31/20214,276548655759N/A
12/31/20204,019505671789N/A
9/30/20203,873478452589N/A
6/30/20203,620442165415N/A
3/31/20203,618420234512N/A
12/31/20193,709410257520N/A
9/30/20193,741381162358N/A
6/30/20193,723352313455N/A
3/31/20193,628319275422N/A
12/31/20183,62230124193N/A
9/30/20183,51427774316N/A
6/30/20183,33724927204N/A
3/31/20183,116231-5116N/A
12/31/20172,853207N/A179N/A
9/30/20172,671187N/A205N/A
6/30/20172,572168N/A125N/A
3/31/20172,547149N/A133N/A
12/31/20162,504146N/A156N/A
9/30/20162,457135N/A214N/A
6/30/20162,504123N/A243N/A
3/31/20162,441108N/A257N/A
12/31/20152,480107N/A200N/A
9/30/20152,46688N/A257N/A
6/30/20152,46171N/A269N/A
3/31/20152,47360N/A118N/A
12/31/20142,47157N/A142N/A
9/30/20142,40845N/A3N/A
6/30/20142,37038N/A62N/A
3/31/20142,37351N/A59N/A
12/31/20132,31561N/A63N/A
9/30/20132,32678N/A25N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: 002332's forecast earnings growth (20% per year) is above the savings rate (2.9%).

Guadagni vs Mercato: 002332's earnings (20% per year) are forecast to grow slower than the CN market (21.9% per year).

Guadagni ad alta crescita: 002332's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: 002332's revenue (14.7% per year) is forecast to grow faster than the CN market (13.4% per year).

Ricavi ad alta crescita: 002332's revenue (14.7% per year) is forecast to grow slower than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: 002332's Return on Equity is forecast to be low in 3 years time (12.3%).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y